Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2010
Errors in Research Letter. The Research Letter titled “Microbiologic Assessment of Multidose Restylane for Facial Augmentation,” published in the July/August 2009 issue of the Archives (2009;11:271-273) contained several errors. The manufacturer of Restylane should have read Q-Med AB, not Q-Medical. The first sentence of the last paragraph of the “Methods” section should have read “For the final aspect of the experiment, 2 syringes of Restylane were seeded with 102 and 105 [rather than 102 and 105, respectively] colony forming units (CFUs) per milliliter of Staphylococcus epidermidis, respectively.” The last paragraph of the “Results” section should have read “In the vial seeded with S epidermidis, 102 [rather than 102] CFUs/mL, no bacteria were recovered after 6 hours. In the vial seeded with S epidermidis, 105 [rather than 105] CFUs/mL, the bacterial count notably decreased over the 24-hour time frame, and the final count at 24 hours was 60 CFUs/mL.” Finally, the last author's medical degrees should have included FRCSC and FACS, and his name was missing the first initial, “S.” S. Mark Taylor, MD, FRCSC, FACS, is the correct presentation.
Errors in Research Letter in: Microbiologic Assessment of Multidose Restylane for Facial Augmentation. Arch Facial Plast Surg. 2010;12(6):378. doi:10.1001/archfacial.2010.82